Yu-Jung Wei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1850372/publications.pdf

Version: 2024-02-01

		567281	580821
39	715	15	25
papers	citations	h-index	g-index
39	39	39	1082
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Association of Chronic Obstructive Pulmonary Disease Maintenance Medication Adherence With All-Cause Hospitalization and Spending in a Medicare Population. American Journal of Geriatric Pharmacotherapy, 2012, 10, 201-210.	3.0	102
2	Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. Inflammatory Bowel Diseases, 2019, 25, 1417-1427.	1.9	89
3	Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. Annals of the American Thoracic Society, 2016, 13, 1497-1504.	3.2	40
4	Body weight, frailty, and chronic pain in older adults: a cross-sectional study. BMC Geriatrics, 2019, 19, 143.	2.7	39
5	Algorithm for Identifying Nursing Home Days Using Medicare Claims and Minimum Data Set Assessment Data. Medical Care, 2016, 54, e73-e77.	2.4	36
6	Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Populationâ€Based Cohort Study. Clinical Pharmacology and Therapeutics, 2020, 108, 81-89.	4.7	33
7	Quality of psychopharmacological medication use in nursing home residents. Research in Social and Administrative Pharmacy, 2014, 10, 494-507.	3.0	30
8	Antiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson's Disease. Clinical Therapeutics, 2013, 35, 1513-1525.e1.	2.5	27
9	Antiparkinson Drug Adherence and Its Association with Health Care Utilization and Economic Outcomes in a Medicare Part D Population. Value in Health, 2014, 17, 196-204.	0.3	24
10	Adherence and healthcare utilization among older adults with COPD and depression. Respiratory Medicine, 2017, 129, 53-58.	2.9	22
11	Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Network Open, 2018, 1, e181152.	5.9	22
12	Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study. PLoS Medicine, 2019, 16, e1002941.	8.4	21
13	Quality of Psychopharmacological Medication Prescribing and Mortality in Medicare Beneficiaries in Nursing Homes. Journal of the American Geriatrics Society, 2014, 62, 1490-1504.	2.6	20
14	The association of antidepressant treatment with COPD maintenance medication use and adherence in a comorbid Medicare population: A longitudinal cohort study. International Journal of Geriatric Psychiatry, 2018, 33, e212-e220.	2.7	17
15	Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Residents With Dementia. Journal of the American Medical Directors Association, 2021, 22, 2079-2086.e5.	2.5	17
16	Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility. Drug Safety, 2020, 43, 329-338.	3.2	15
17	Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease. American Journal of Geriatric Pharmacotherapy, 2010, 8, 384-394.	3.0	14
18	Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtractâ€"Quantifying the misclassification of maternal drug exposure during pregnancy. Pharmacoepidemiology and Drug Safety, 2020, 29, 1414-1422.	1.9	14

#	Article	IF	CITATIONS
19	Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias. Journal of the American Geriatrics Society, 2015, 63, 1757-1765.	2.6	13
20	Mortality Risk of Antipsychotic Dose and Duration in Nursing Home Residents with Chronic or Acute Indications. Journal of the American Geriatrics Society, 2016, 64, 973-980.	2.6	12
21	Relationships between antiparkinson medication nonadherence, regimen modifications, and healthcare utilization and expenditures. Parkinsonism and Related Disorders, 2015, 21, 36-41.	2.2	10
22	Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: An interrupted time series analysis. Drug and Alcohol Dependence, 2019, 202, 172-177.	3.2	10
23	Utilization Patterns of Skeletal Muscle Relaxants Among Commercially Insured Adults in the United States from 2006 to 2018. Pain Medicine, 2021, 22, 2153-2161.	1.9	9
24	Quality of opioid prescribing in older adults with or without Alzheimer disease and related dementia. Alzheimer's Research and Therapy, 2021, 13, 78.	6.2	9
25	Fall and Fracture Risk in Nursing Home Residents With Moderate-to-Severe Behavioral Symptoms of Alzheimer's Disease and Related Dementias Initiating Antidepressants or Antipsychotics. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw095.	3.6	8
26	Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study. Otology and Neurotology, 2018, 39, 957-963.	1.3	8
27	Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016. Drug and Alcohol Dependence, 2019, 204, 107600.	3.2	8
28	Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: A population-based cohort study. PLoS Medicine, 2022, 19, e1003921.	8.4	8
29	Trajectories of prescription opioid dose and risk of opioid-related adverse events among older Medicare beneficiaries in the United States: A nested case–control study. PLoS Medicine, 2022, 19, e1003947.	8.4	7
30	Performance of the Centers for Medicare & Description Services' Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose. JAMA - Journal of the American Medical Association, 2019, 321, 609.	7.4	6
31	Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 833-839.	1.3	5
32	Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration. Pharmacotherapy, 2019, 39, 1042-1052.	2.6	5
33	Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults. American Journal of Preventive Medicine, 2022, 62, 519-528.	3.0	5
34	Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home. Aging and Mental Health, 2021, 25, 1897-1902.	2.8	4
35	Discontinuation of Long-Term Opioid Therapy in Patients With Versus Without Dementia. American Journal of Preventive Medicine, 2022, 62, 270-274.	3.0	3
36	Perioperative Use of Gabapentinoids and Risk for Postoperative Long-Term Opioid Use in Older Adults Undergoing Total Knee or Hip Arthroplasty. Journal of Arthroplasty, 2022, 37, 2149-2157.e3.	3.1	2

Yu-Jung Wei

#	Article	IF	CITATIONS
37	Clinical utility and perils of prescription drug monitoring program–based alert systems. Pain, 2018, 159, 804-805.	4.2	1
38	O4-13-04: ANTIPSYCHOTICS AND OTHER PSYCHOPHARMACOLOGICAL MEDICATION USE IN UNITED STATES NURSING HOMES: WHAT ARE THE CONCERNS AND ACTIONS TAKING PLACE TO OPTIMIZE PRESCRIBING?. , 2014, 10, P278-P279.		0
39	Response to Lapane and Colleagues. Journal of the American Geriatrics Society, 2015, 63, 834-834.	2.6	0